tiprankstipranks
Trending News
More News >
Delta-Fly Pharma, Inc. (JP:4598)
:4598
Japanese Market
Advertisement

Delta-Fly Pharma, Inc. (4598) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4598

Delta-Fly Pharma, Inc.

(4598)

Rating:28Underperform
Price Target:
Delta-Fly Pharma, Inc. is currently facing significant financial and operational challenges, with no recent revenue and ongoing losses. While the lack of debt provides some financial cushion, the absence of operating cash flow is a major concern. Technically, the stock shows a neutral to slightly bearish trend, and valuation metrics are unfavorable due to negative earnings. These factors combine to produce a low overall stock score, reflecting the high risks associated with investing in this early-stage biotech company.

Delta-Fly Pharma, Inc. (4598) vs. iShares MSCI Japan ETF (EWJ)

Delta-Fly Pharma, Inc. Business Overview & Revenue Model

Company DescriptionDelta-Fly Pharma, Inc. (4598) is a pharmaceutical company headquartered in Japan. The company focuses on the research and development of innovative cancer treatments, leveraging its expertise in drug discovery and clinical development. Delta-Fly Pharma aims to address unmet medical needs in oncology through its pipeline of novel therapeutic candidates. The company's core products and services revolve around its proprietary compounds that are designed to improve the efficacy and safety of existing cancer therapies.
How the Company Makes MoneyDelta-Fly Pharma, Inc. generates revenue primarily through the development and commercialization of its pharmaceutical products. The company's revenue streams include out-licensing agreements, collaborative partnerships, and milestone payments from pharmaceutical companies that partner with Delta-Fly Pharma to further develop and market its drug candidates. Additionally, the company may earn income from royalties on product sales once its therapeutic candidates receive regulatory approval and are commercialized. Strategic alliances and research partnerships are significant factors contributing to Delta-Fly Pharma's earnings, enabling the company to leverage the resources and expertise of larger pharmaceutical firms to bring its innovations to market.

Delta-Fly Pharma, Inc. Financial Statement Overview

Summary
Delta-Fly Pharma, Inc. is facing significant financial challenges, characterized by a lack of revenue in recent periods and persistent operational losses. The strong equity position, due to no debt, offers some buffer, but the absence of cash flow from operations is concerning. The biotech industry often involves high risk and substantial investment before profitability, and this company appears to be in the early stages of this cycle, with potential liquidity risks.
Income Statement
10
Very Negative
Delta-Fly Pharma, Inc. shows no revenue in the TTM period, leading to a lack of profitability metrics such as gross profit margin and net profit margin. The company has experienced a significant decline in revenue from 2022, with consistent negative EBIT and EBITDA, indicating ongoing operational losses. Revenue growth is negative due to the absence of revenue, which poses a challenge for financial sustainability.
Balance Sheet
60
Neutral
The balance sheet reflects a strong equity position with no debt, resulting in a debt-to-equity ratio of 0, which is typically favorable. However, the company’s significant losses have eroded stockholders' equity over time. The equity ratio remains high, indicating reliance on equity financing. While the lack of debt reduces financial risk, ongoing losses may threaten future stability.
Cash Flow
15
Very Negative
The company’s cash flow statement reveals an absence of free cash flow growth and operating cash flow. The lack of operating cash flow is concerning and suggests that the company is not generating cash from its core activities. Free cash flow remains negative, indicating potential liquidity challenges. The absence of cash flow from operations to support net income is a significant risk.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue0.000.000.000.00300.00M300.00M
Gross Profit-1.59M-1.59M-1.51M-1.63M300.00M300.00M
EBITDA-1.70B-1.72B-1.40B-1.32B-960.00M-857.32M
Net Income-1.72B-1.72B-1.43B-1.33B-967.30M-862.59M
Balance Sheet
Total Assets434.33M434.33M1.47B906.82M1.32B2.16B
Cash, Cash Equivalents and Short-Term Investments338.83M338.83M1.42B844.34M1.27B2.09B
Total Debt0.000.000.000.000.000.00
Total Liabilities156.54M156.54M241.50M115.62M91.19M82.46M
Stockholders Equity277.80M277.80M1.23B791.20M1.23B2.08B
Cash Flow
Free Cash Flow0.00-1.83B-1.28B-1.30B-940.40M-727.15M
Operating Cash Flow0.00-1.83B-1.28B-1.30B-940.40M-726.65M
Investing Cash Flow0.00-206.00K207.00K-326.00K0.00-505.00K
Financing Cash Flow0.00756.70M1.85B882.62M119.86M875.31M

Delta-Fly Pharma, Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price598.00
Price Trends
50DMA
673.24
Negative
100DMA
609.87
Negative
200DMA
588.90
Positive
Market Momentum
MACD
-24.16
Negative
RSI
40.83
Neutral
STOCH
49.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4598, the sentiment is Negative. The current price of 598 is below the 20-day moving average (MA) of 617.40, below the 50-day MA of 673.24, and above the 200-day MA of 588.90, indicating a neutral trend. The MACD of -24.16 indicates Negative momentum. The RSI at 40.83 is Neutral, neither overbought nor oversold. The STOCH value of 49.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4598.

Delta-Fly Pharma, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
¥8.58B
1254.76%33.94%
54
Neutral
¥3.48B
-8.56%-7.26%
51
Neutral
$7.95B-0.40-42.50%2.21%22.29%-1.85%
48
Neutral
¥9.66B
30.92%26.00%
44
Neutral
¥16.59B
-9.04%2.12%
28
Underperform
¥6.89B
20.41%
€52.30M-96.20%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4598
Delta-Fly Pharma, Inc.
598.00
34.00
6.03%
DE:30O
OncoTherapy Science
0.14
-0.06
-30.00%
JP:4583
Chiome Bioscience Inc.
142.00
38.00
36.54%
JP:4588
Oncolys BioPharma, Inc.
647.00
56.00
9.48%
JP:4594
BrightPath Biotherapeutics Co.Ltd.
77.00
25.00
48.08%
JP:4884
Kringle Pharma, Inc.
497.00
-359.00
-41.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 29, 2025